China Pushes For Lower Sovaldi Prices Amid Rising HCV Cases
This article was originally published in PharmAsia News
Excluded from an access program targeting low-income countries, China is now working to secure lower prices for hepatitis C drug Sovaldi via negotiations with manufacturer Gilead Sciences, hoping to bring the highly effective therapy to the country early, local health officials have disclosed.
You may also be interested in...
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.
With gene editing making the news again after the recent Nobel Prize for CRISPR, China’s EdiGene has been raising new funds to accelerate its pipeline to the clinic, led by a potential one-time cure for thalassemia and helped by recent regulatory changes.
Given the high number of such trials in the country, China’s National Medical Products Administration has released separate guidelines for industry on the development of gene and cell therapies and gene editing clinical research.